ACTGNetwork

RSS
In this week’s World Wednesday post we look using HIV self-testing kits at home in South Africa. Nearly all of the study participants successfully completed the test, proving the tests provide earlier detection of infection and are a cost-effective alternative to oral fluid tests. Researchers say the study results prove that it may be ideal for scaling up HIV self-testing in resource-limited settings.
#hiv #aids #southafrica #worldwednesday #gettested http://ift.tt/XfefE3

In this week’s World Wednesday post we look using HIV self-testing kits at home in South Africa. Nearly all of the study participants successfully completed the test, proving the tests provide earlier detection of infection and are a cost-effective alternative to oral fluid tests. Researchers say the study results prove that it may be ideal for scaling up HIV self-testing in resource-limited settings.
#hiv #aids #southafrica #worldwednesday #gettested http://ift.tt/XfefE3

HIV Self-Testing Viable in Rural South Africa

In this week’s World Wednesday post we look at two studies from South Africa. One investigated whether South Africans would be comfortable using HIV self-testing kits at home. The second study explored the feasibility of treatment as prevention in South Africa.

Although it has well-known psychiatric side effects, the HIV drug efavirenz (Sustiva) does not affect cognition, according to a report released during the International AIDS Conference.
#hiv #aids #cognition #aids2014 http://ift.tt/1nD6sKg

Although it has well-known psychiatric side effects, the HIV drug efavirenz (Sustiva) does not affect cognition, according to a report released during the International AIDS Conference.
#hiv #aids #cognition #aids2014 http://ift.tt/1nD6sKg

Although it has well-known psychiatric side effects, the HIV drug efavirenz (Sustiva) does not affect cognition, according to a report released during the International AIDS Conference.

Although it has well-known psychiatric side effects, the HIV drug efavirenz (Sustiva) does not affect cognition, according to a report released during the International AIDS Conference.

(Source: medpagetoday.com)

Today is World Hepatitis Day. There are more than 500 million people globally living with hepatitis. Head to our website to learn about two enrolling studies into treating hepatitis C. actgnetwork.org.  #hiv #hcv #hepatitis #aids #thinkhepatitis http://ift.tt/1mUMllZ

Today is World Hepatitis Day. There are more than 500 million people globally living with hepatitis. Head to our website to learn about two enrolling studies into treating hepatitis C. actgnetwork.org. #hiv #hcv #hepatitis #aids #thinkhepatitis http://ift.tt/1mUMllZ

World Hepatitis Day

People living with HIV on stable antiretroviral regimens who switch to another therapy have a significantly increased risk of experiencing HIV virologic failure on the new regimen compared with non-switchers, according to a study at the International AIDS Conference. #aids #hiv #aids2014 http://ift.tt/1nGp8K7

People living with HIV on stable antiretroviral regimens who switch to another therapy have a significantly increased risk of experiencing HIV virologic failure on the new regimen compared with non-switchers, according to a study at the International AIDS Conference. #aids #hiv #aids2014 http://ift.tt/1nGp8K7

Rx Switching Tied to HIV Viral Breakthrough

People living with HIV on stable antiretroviral regimens who switch to another therapy have a significantly increased risk of experiencing HIV virologic failure on the new regimen compared with non-switchers, according to a study at the International AIDS Conference. 

Our Dr. Diane Havlir presented Wednesday at the International AIDS Conference in Australia about researching shorter courses of tuberculosis treatment. TB is the number one killer of people living with HIV globally and the long course of treatment makes adherence tough.
#aids2014 #hiv #aids #tb #research #science #health http://ift.tt/1uiBBqU

Our Dr. Diane Havlir presented Wednesday at the International AIDS Conference in Australia about researching shorter courses of tuberculosis treatment. TB is the number one killer of people living with HIV globally and the long course of treatment makes adherence tough.
#aids2014 #hiv #aids #tb #research #science #health http://ift.tt/1uiBBqU

Watch Dr. Carl Dieffenbach from the US National Institute of Allergy and Infectious Diseases discuss our Dr. Diane Havlir’s research into tuberculosis and President Clinton’s work making anti-HIV medications accessible.